Next Phase Newsletter

A tech-driven pharmaceutical company based in the U.S. leverages its AI-powered drug development platform, the firm seeks to acquire promising drug candidates and develop them in-house faster and more efficiently than industry norms. The firm is interested in early clinical-stage therapeutic assets, and its typical deal structures include acquisitions and in-licensing. While equity investments are occasionally possible, the firm prefers to take a majority share and does not typically act as a minority investor. The firm is open to opportunities globally. 
 
The firm is interested in traditional therapeutic assets such as small molecules and biologics, with a primary focus on immunology, dermatology, and orphan diseases. Other indications of interest include CNS, cardiovascular, and metabolic diseases. The firm generally avoids cell therapy and oncology. As for development phases, the earliest the firm will consider is within 12 months of IND, with no limitation on how late the asset is in the clinical stage. 
 
The firm does not have specific requirements for a company’s management team, as the firm aims to take over the asset and typically does not act as a minority investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment management firm is led by partners who have been co-founders / founding executives of successfully exited healthtech companies, with expertise spanning various fields of life sciences. The firm is an active investor in life sciences & healthcare, and is open to all stages of development. Typical investment size is $1-2M for early stage companies, though the size can go up to over $10M in later-stage companies. The firm is open to global opportunities. 
 
The firm invests broadly across therapeutics, medical devices, diagnostics, and digital health, with stronger interests in the first 3 sectors listed. The firm seeks first-in-class / best-in-class technologies that address unmet medical need. In terms of indication, oncology is less of a priority, but is still considered. The firm is open to reviewing both pre-clinical and clinical stage technologies. 
 
The firm seeks to work with companies backed by a committed management team. The firm can act as either a lead/co-lead or co-investor. The firm is capable of getting other family offices involved in forming a syndicate on a deal-by-deal basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A US subsidiary of a mid-sized pharma company in Asia has a robust pipeline of antibody-based and small molecule therapeutics. The firm is currently seeking strategic partnerships involving next-gen technology platforms and novel targets and molecules in the fields of oncology, autoimmune, metabolic, cardiovascular, and other disease areas with unmet medical needs. As one of the leaders in the field of antibody-drug conjugates (ADCs), there is particular interest in partnering with early-stage biotechs that are developing first-in-class antibodies. 
 
The firm is primarily interested in licensing or co-developing antibody-based therapeutics, including those with novel targets, structures/designs, conjugation chemistries, and linker-payload strategies. 
 
The firm has no specific requirements for the company and management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm backed by a prominent family office currently manages a fund that is focused exclusively on life sciences & healthcare. The firm is focused on investing early-stage companies and open to global opportunities. 
 
The firm seeks to invest in therapeutics, diagnostics, and digital health companies and has no particular preference on specific types of technologies or disease area/indication. The firm prefers to see strong pre-clinical data, and is open to both pre-clinical and clinical projects. The firm does not invest in medical device companies at this time. In addition, the firm invests in other venture capital firms.  
 
The firm seeks to support companies with innovative technology, and is open to working with both first-time and experienced management teams. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A seed fund based in the US focuses on applied AI technologies and invests in three verticals: Digital Health, Enterprise, and Automation. The firm invests $ 500K – $1.5M in seed-stage companies based in the US with capital reserved for follow-ons. 
 
Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will co Calibri (Body) nsider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery. 
 
The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture studio and investment firm based in Asia currently manages a portfolio with half of the companies from their country of origin, and the half from across the globe (mostly USA, but some in Europe and Asia). The firm invests primarily in Seed to Pre-Series A rounds and focuses on life science and healthcare investments, with typical check sizes around $1-2M. The firm actively seeks global opportunities. 
 
The firm is agnostic towards sectors and indication areas. The firm has invested across all life science sectors, with a diverse portfolio in therapeutics, medical devices, diagnostics, and digital health. As an early-stage focused investor, the firm welcomes projects that are as early as idea or conception stage, and is open to pre-clinical stage companies.  

Previously, the firm had a focus on oncology, infectious disease, cardiovascular disease, and CNS. Regarding diagnostics, the firm had an additional focus on -omics and AI-based diagnostics, as well as infectious disease point-of-care diagnostics. For digital health, the firm is interested in precision medicine drug discovery, wearable sensors, digital therapeutics, home healthcare, and hospital tools. 
 
Though the firm does not have specific areas of interest and has broad interests in life sciences, the firm prioritizes areas with truly unmet need where there has not been enough advancements in delivering a therapeutic solution, and looks for novel technologies that have the potential to address a wide market. To date, the firm has not led investment rounds, but is open to co-leading in the future.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.